STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) today announces that the Board of
Directors has appointed Jens
Lindberg as CEO of the company. Jens
Lindberg has extensive experience from the pharmaceutical
industry and the field of Oncology. He joins from Sedana Medical
where he has been VP Commercial and acting CEO.
Jens Lindberg started his career
in the pharmaceutical industry in 1995 as a sales representative
for Astra, later AstraZeneca. During a 25-year span at AstraZeneca,
Jens held numerous roles in Commercial & Investor Relations,
spanning local & global responsibilities as well as development
of phase 2/3 programs to maximise the commercial value for
on-market brands. During his last 10 years at AstraZeneca, his
roles were primarily in the area of Oncology across multiple tumor
types, driving global strategy and product development as global
commercial lead, and running local Business Unit Oncology in
Nordic-Baltic region with significant commercial success.
Since early 2020 Jens has been responsible for commercial
efforts at Sedana Medical with the focus of building up the
company's pharmaceutical capabilities and readiness for its first
commercial launch in early 2022. In addition, during Q2-Q3 he held
the role of Acting CEO for Sedana Medical.
- "It is with great enthusiasm I will assume the CEO position at
Medivir" stated Jens Lindberg.
"Medivir is in a very exciting phase with focus on developing
innovative drugs for the treatment of cancer. Medivirs lead product
candidate, MIV-818, is a product candidate with great potential. I
am excited about leading the Medivir team as we expand the
development program for MIV-818 and maximise the value of our other
programs through strategic collaborations and
partnerships."
- "I am delighted about our recruitment of Jens Lindberg as CEO. He has the ideal
personality and experience for this job. Jens brings relevant
skills both when it comes to building successful organizations and
in developing and commercializing medicines for the treatment of
cancer," says Dr Uli Hacksell,
Chairman of the Board for Medivir AB.
Jens Lindberg will assume the
position as CEO within six months. Magnus
Christensen will continue as interim CEO until Jens starts
at Medivir.
For further information, please contact:
Dr Uli Hacksell, Chairman of
the Board, Medivir AB, Phone: +46 (0)8 5468 3100.
uli.hacksell@medivir.com
Medivir AB is obliged to make this information public
pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the
agency of the contact person set out above, at 08.30 CET on
October 25, 2021
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-appoints-jens-lindberg-as-chief-executive-officer,c3439061
The following files are available for download:
|
https://mb.cision.com/Main/652/3439061/1485435.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivir-appoints-jens-lindberg-as-chief-executive-officer-301407320.html
SOURCE Medivir
